Soto Ocaña Joshua, Bayard Nile U, Zackular Joseph P
Division of Protective Immunity, Children's Hospital of Philadelphia, Philadelphia, PA, United States; Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States.
Division of Protective Immunity, Children's Hospital of Philadelphia, Philadelphia, PA, United States.
Curr Opin Microbiol. 2022 Feb;65:167-174. doi: 10.1016/j.mib.2021.11.011. Epub 2021 Dec 8.
Clostridioides difficile is one of the leading causes of nosocomial infections worldwide. Increases in incidence, severity, and healthcare cost associated with C. difficile infection (CDI) have made this pathogen an urgent public health threat worldwide. The factors shaping the evolving epidemiology of CDI and impacting clinical outcomes of infection are not well understood, but involve tripartite interactions between the host, microbiota, and C. difficile. In addition to this, emerging data suggests an underappreciated role for environmental factors, such as diet and pharmaceutical drugs, in CDI. In this review, we discuss the role of nonsteroidal anti-inflammatory drugs (NSAIDs) and eicosanoids in CDI.
艰难梭菌是全球医院感染的主要原因之一。艰难梭菌感染(CDI)的发病率、严重程度及医疗成本不断上升,使这种病原体成为全球紧迫的公共卫生威胁。目前尚不清楚影响CDI流行病学演变及感染临床结局的因素,但这些因素涉及宿主、微生物群和艰难梭菌之间的三方相互作用。除此之外,新出现的数据表明,饮食和药物等环境因素在CDI中发挥着未被充分认识的作用。在本综述中,我们讨论非甾体抗炎药(NSAIDs)和类花生酸在CDI中的作用。